Search results
Stuart Schreiber is a Morris Loeb Professor of Chemistry and Chemical Biology, Emeritus, and a Howard Hughes Medical Institute Investigator. His lab studies the science of therapeutics, including drug discovery, cell signaling, gene regulation, and brain health.
Stuart Schreiber is an American chemist who is the Morris Loeb Research Professor at Harvard University, a co-Founder of the Broad Institute, Howard Hughes Medical Institute Investigator, Emeritus, and a member of the National Academy of Sciences and National Academy of Medicine.
Stuart Schreiber is a pioneer of chemical biology and a co-founder of the Broad Institute. He discovered molecular glues, PROTACs, and other small molecules that modulate biological processes and disease.
The Schreiber lab led by Stuart Schreiber uses chemical biology and human biology to discover small-molecule probes and therapeutics for various diseases. Learn about their areas of focus, such as next-generation synthesis, cancer and microbial therapeutics, and novel mechanisms of action.
Mar 1, 2024 · Stuart Schreiber, a chemist and co-founder of The Broad Institute, discusses his plans to tackle inefficiencies in the translation of biomedical research, through the newly launched for-profit institute Arena BioWorks. He explains how Arena aims to speed up the discovery and development of new medicines for diseases such as brain health, oncology and ageing.
- Asher Mullard
Morris Loeb professor of chemistry Stuart L. Schreiber is a member of the department of chemistry and chemical biology, as well as a co-founder of the Broad Institute of Harvard and MIT, a member of the National Academy of Sciences and National Academy of Medicine, and a recent recipient of the Wolf Prize in Chemistry.
People also ask
What is a Schreiber lab?
Who is Stuart Schreiber?
Why is Schreiber important?
What does Stuart Schreiber do to tackle inefficiencies in biomedical research?
Stuart Schreiber. Morris Loeb Professor of Chemistry and Chemical Biology. Summary. Description. By examining a series of alleles linked to a disease, we can learn the effect of modulating candidate therapeutic targets in terms of both efficacy and safety.
